{"id":506300,"date":"2020-09-10T13:44:01","date_gmt":"2020-09-10T13:44:01","guid":{"rendered":"https:\/\/www.abnewswire.com\/pressreleases\/?p=506300"},"modified":"2020-09-10T13:44:01","modified_gmt":"2020-09-10T13:44:01","slug":"acute-respiratory-distress-syndrome-ards-market-size-trends-epidemiology-forecast-till-2030","status":"publish","type":"post","link":"https:\/\/www.abnewswire.com\/pressreleases\/acute-respiratory-distress-syndrome-ards-market-size-trends-epidemiology-forecast-till-2030_506300.html","title":{"rendered":"Acute Respiratory Distress Syndrome (ARDS) Market, Size, Trends, Epidemiology Forecast till 2030"},"content":{"rendered":"
\"Acute<\/a><\/p>\n
\n
DelveInsight Business Research LLP <\/div>\n<\/div>\n<\/div>\n
DelveInsight’s “ARDS Market Insights, Epidemiology, and Market Forecast-2030” report delivers an in-depth understanding of the ARDS, historical and forecasted epidemiology as well as the ARDS market trends in the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom) and Japan.<\/div>\n

Acute Respiratory Distress Syndrome (ARDS) is a rapidly progressive disease occurring in critically ill patients.<\/p>\n

ARDS Market Outlook<\/strong><\/p>\n

The ARDS market outlook<\/strong><\/a> of the report helps to build the detailed comprehension of the historic, current, and forecasted ARDS <\/span>market <\/span>trends by analyzing the impact of current therapies on the market, unmet needs, drivers and barriers and demand of better technology.<\/p>\n

This segment gives a thorough detail of ARDS <\/span>market trend of each marketed drug and late-stage pipeline therapy by evaluating their impact based on annual cost of therapy, inclusion and exclusion criteria’s, mechanism of action, compliance rate, growing need of the market, increasing patient pool, covered patient segment, expected launch year, competition with other therapies, brand value, their impact on the market and view of the key opinion leaders. The calculated market data are presented with relevant tables and graphs to give a clear view of the market at first sight. <\/p>\n

The therapeutic market of Acute Respiratory Distress Syndrome (ARDS) in the seven major markets was USD 918.2 Million<\/strong><\/a> in 2017. The United States accounts for the highest market size of Acute Respiratory Distress Syndrome (ARDS), in comparison to the other 7 Major Markets, i.e., EU5 countries and Japan. Among the EU5 countries, Germany contributed the largest market share in EU5 countries, with 52.02%, followed by Italy (15.68%) in 2017.<\/p>\n

Despite decades of research, treatment options for ARDS are restricted. Supportive care with mechanical ventilation remains the mainstay of management. There are relatively few treatments available for ARDS.<\/p>\n

Other treatment options, which the patients with ARDS are generally subjected include supplemental oxygen, prone positioning, use of paralytics, fluid management, and a technique called positive end-expiratory pressure (PEEP) to help push the fluid out of air sacs. These are combined with continuing treatment of the original illness or injury. Because people with ARDS are less able to fight lung infections, they may develop bacterial pneumonia during the illness. Antibiotics are given to fight infection. Also, supportive treatment, such as intravenous fluid or food, may be needed.<\/p>\n

Alveolar flooding and pulmonary edema formation are important pathophysiological derangements in patients with ARDS. Experimental data have shown that β2 agonists can increase sodium transport by activating β2 receptors on alveolar type I and type II cells, accelerating the resolution of pulmonary edema.<\/p>\n

Because injury to the alveolar epithelium is a significant cause of ARDS, the acceleration of alveolar epithelial repair may assist the resolution of pulmonary edema and lung injury. Keratinocyte growth factor (KGF) is important in alveolar epithelial repair, and experimental and human studies support the concept that KGF may be beneficial in patients with ARDS.<\/p>\n

Inflammation is an additional pathological hallmark of ARDS and may contribute to both pulmonary and non-pulmonary organ failure. Statins—a class of drugs which is often prescribed by doctors to help decrease cholesterol levels in the blood—can decrease inflammation and development of lung injury in experimental models. By lowering the levels, heart attacks, and stroke can be prevented. Several studies show that, in certain people, statins reduce the risk of heart attack, stroke, and even death from heart disease. However, some studies contradict their use in the management of ARDS because statins neither provide benefit for lowering the morbidity of ARDS in high-risk patients nor improve the clinical outcomes of ALI\/ARDS patients. Hence, it may not be appropriate to advocate statin use for the prevention and treatment of ALI\/ARDS.<\/p>\n

Mechanical ventilation (MV) is the foundation of ARDS management. The use of protective ventilation is a priority in this acute phase of lung inflammation. According to various studies, neuromuscular blocking agents (NMBAs) play an important role in the management of a large number of hospital patients. NMBAs induces reversible muscle paralysis. Their use in patients with ARDS remains controversial but occurs frequently. In addition to their routine use in surgical anesthesia, NMBAs may be valuable in many new and evolving critical care situations. NMBAs exert their pharmacologic effects by modulating signal transmission in skeletal muscle. Action potentials reaching skeletal muscle activates the release of acetylcholine into the motor endplates.<\/p>\n

 <\/p>\n

Request for sample pages<\/strong><\/a>
Table of contents<\/strong><\/a><\/p>\n

1. Key Insights<\/span><\/p>\n

2. Executive Summary of ARDS<\/span><\/p>\n

3. Competitive Intelligence Analysis for ARDS<\/span><\/p>\n

4. ARDS: Market Overview at a Glance<\/span><\/p>\n

4.1. ARDS Total Market Share (%) Distribution in 2017<\/span><\/p>\n

4.2. ARDS Total Market Share (%) Distribution in 2030<\/span><\/p>\n

5. ARDS: Disease Background and Overview<\/span><\/p>\n

5.1. Introduction<\/span><\/p>\n

5.2. Sign and Symptoms <\/span><\/p>\n

5.3. Pathophysiology <\/span><\/p>\n

5.4. Risk Factors <\/span><\/p>\n

5.5. Diagnosis <\/span><\/p>\n

6. Patient Journey<\/span><\/p>\n

7. ARDS Epidemiology and Patient Population<\/span><\/p>\n

7.1. Epidemiology Key Findings<\/span><\/p>\n

7.2. Assumptions and Rationale: 7MM<\/span><\/p>\n

7.3. Epidemiology Scenario: 7MM<\/span><\/p>\n

7.3.1. ARDS Epidemiology Scenario in the 7MM (2017-2030)<\/span><\/p>\n

7.4. United States Epidemiology<\/span><\/p>\n

7.4.1. ARDS Epidemiology Scenario in the United States (2017-2030)<\/span><\/p>\n

7.5. EU-5 Country-wise Epidemiology<\/span><\/p>\n

7.5.1. Germany Epidemiology<\/span><\/p>\n

7.5.1.1. ARDS Epidemiology Scenario in Germany (2017-2030)<\/span><\/p>\n

7.5.2. France Epidemiology<\/span><\/p>\n

7.5.2.1. ARDS Epidemiology Scenario in France (2017-2030)<\/span><\/p>\n

7.5.3. Italy Epidemiology<\/span><\/p>\n

7.5.3.1. ARDS Epidemiology Scenario in Italy (2017-2030)<\/span><\/p>\n

7.5.4. Spain Epidemiology<\/span><\/p>\n

7.5.4.1. ARDS Epidemiology Scenario in Spain (2017-2030)<\/span><\/p>\n

7.5.5. United Kingdom Epidemiology<\/span><\/p>\n

7.5.5.1. ARDS Epidemiology Scenario in the United Kingdom (2017-2030)<\/span><\/p>\n

7.5.6. Japan Epidemiology<\/span><\/p>\n

7.5.6.1. ARDS Epidemiology Scenario in Japan (2017-2030)<\/span><\/p>\n

8. Treatment Algorithm, Current Treatment, and Medical Practices<\/span><\/p>\n

8.1. ARDS Treatment and Management<\/span><\/p>\n

8.2. ARDS Treatment Algorithm <\/span><\/p>\n

9. Unmet Needs<\/span><\/p>\n

10. Key Endpoints of ARDS Treatment<\/span><\/p>\n

11. Marketed Products<\/span><\/p>\n

11.1. List of Marketed Products in the 7MM<\/span><\/p>\n

11.2. Drug Name: Company Name<\/span><\/p>\n

11.2.1. Product Description<\/span><\/p>\n

11.2.2. Regulatory Milestones<\/span><\/p>\n

11.2.3. Other Developmental Activities<\/span><\/p>\n

11.2.4. Pivotal Clinical Trials<\/span><\/p>\n

11.2.5. Summary of Pivotal Clinical Trial<\/span><\/p>\n

List to be continued in report<\/span><\/p>\n

12. Emerging Therapies<\/span><\/p>\n

12.1. Key Cross<\/span><\/p>\n

12.2. Drug Name: Company Name<\/span><\/p>\n

12.2.1. Product Description<\/span><\/p>\n

12.2.2. Other Developmental Activities<\/span><\/p>\n

12.2.3. Clinical Development<\/span><\/p>\n

12.2.4. Safety and Efficacy<\/span><\/p>\n

12.2.5. Product Profile<\/span><\/p>\n

List to be continued in report<\/span><\/p>\n

13. ARDS: Seven Major Market Analysis<\/span><\/p>\n

13.1. Key Findings<\/span><\/p>\n

13.2. ARDS Market Size in 7MM<\/span><\/p>\n

13.3. ARDS Market Size by Therapies in the 7MM<\/span><\/p>\n

14. Attribute analysis<\/span><\/p>\n

15. 7MM: Market Outlook<\/span><\/p>\n

15.1. United States: Market Size<\/span><\/p>\n

15.1.1. ARDS Total Market Size in the United States<\/span><\/p>\n

15.1.2. ARDS Market Size by Therapies in the United States<\/span><\/p>\n

15.2. EU-5 countries: Market Size and Outlook<\/span><\/p>\n

15.3. Germany Market Size<\/span><\/p>\n

15.3.1. ARDS Total Market Size in Germany<\/span><\/p>\n

15.3.2. ARDS Market Size by Therapies in Germany<\/span><\/p>\n

15.4. France Market Size<\/span><\/p>\n

15.4.1. ARDS Total Market Size in France<\/span><\/p>\n

15.4.2. ARDS Market Size by Therapies in France<\/span><\/p>\n

15.5. Italy Market Size<\/span><\/p>\n

15.5.1. ARDS Total Market Size in Italy<\/span><\/p>\n

15.5.2. ARDS Market Size by Therapies in Italy<\/span><\/p>\n

15.6. Spain Market Size<\/span><\/p>\n

15.6.1. ARDS Total Market Size in Spain<\/span><\/p>\n

15.6.2. ARDS Market Size by Therapies in Spain<\/span><\/p>\n

15.7. United Kingdom Market Size<\/span><\/p>\n

15.7.1. ARDS Total Market Size in the United Kingdom<\/span><\/p>\n

15.7.2. ARDS Market Size by Therapies in the United Kingdom<\/span><\/p>\n

15.8. Japan Market Outlook<\/span><\/p>\n

15.8.1. Japan Market Size<\/span><\/p>\n

15.8.2. ARDS Total Market Size in Japan<\/span><\/p>\n

15.8.3. ARDS Market Size by Therapies in Japan<\/span><\/p>\n

16. Access and Reimbursement Overview of ARDS<\/span><\/p>\n

17. KOL Views<\/span><\/p>\n

18. Market Drivers<\/span><\/p>\n

19. Market Barriers<\/span><\/p>\n

20. Appendix<\/span><\/p>\n

20.1. Bibliography<\/span><\/p>\n

20.2. Report Methodology<\/span><\/p>\n

21. DelveInsight Capabilities<\/span><\/p>\n

22. Disclaimer<\/span><\/p>\n

23. About DelveInsight<\/span><\/p>\n

Media Contact<\/span>
Company Name:<\/strong> DelveInsight<\/a>
Contact Person:<\/strong> Priya Maurya
Email:<\/strong> Send Email<\/a>
Phone:<\/strong> +919650213330
City:<\/strong> Albany
State:<\/strong> New York
Country:<\/strong> United States
Website:<\/strong> https:\/\/www.delveinsight.com\/<\/a><\/p>\n

<\/object>\"\"<\/p>\n","protected":false},"excerpt":{"rendered":"

DelveInsight Business Research LLP DelveInsight’s “ARDS Market Insights, Epidemiology, and Market Forecast-2030” report delivers an in-depth understanding of the ARDS, historical and forecasted epidemiology as well as the ARDS market trends in the United States, EU5 (Germany, Spain, Italy, France, … Continue reading →<\/span><\/a><\/p>\n","protected":false},"author":1,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[406,423,420,403,404],"tags":[],"class_list":["post-506300","post","type-post","status-publish","format-standard","hentry","category-Pharmaceuticals-Biotech","category-Professional-Services","category-Science","category-UK","category-US"],"_links":{"self":[{"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/posts\/506300","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/comments?post=506300"}],"version-history":[{"count":0,"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/posts\/506300\/revisions"}],"wp:attachment":[{"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/media?parent=506300"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/categories?post=506300"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/tags?post=506300"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}